ArticleInternal and emergency medicine2025
Clinical outcomes of chest pain with cocaine use: a propensity score-matched analysis.
Article in Internal and emergency medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cocaine use has been linked to cardiovascular complications due to its vasoconstrictive properties; however, short-term risk of major adverse cardiac events (MACE) in patients presenting with chest pain remains controversial due to limited sample sizes (< 5000 patients). Leveraging the TriNetX database, we analyzed 89,652 patients, providing the largest and most statistically powered evaluation of cocaine-associated chest pain to date. This retrospective, propensity score-matched cohort study used the TriNetX Research Network to identify adults presenting to the ED with chest pain or shortness of breath (March 2005-March 2025). Patients undergoing urine toxicology were matched 1:1 into + COCN and -COCN cohorts. The primary outcome was 30-day composite MACE, including acute myocardial infarction (AMI), acute decompensated heart failure (ADHF), ischemic stroke, and cardiac arrest. The matched cohorts included 44,826 patients each. The + COCN group had statistically higher rates of MACE components, though absolute differences were small: AMI (1.25% vs. 0.30%; Risk Difference [RD] 0.002), ADHF (0.17% vs. 0.07%; RD 0.001), and ischemic stroke (0.32% vs. 0.14%; RD 0.002) (all p < 0.001). Cardiac arrest was also more frequent (0.14% vs. 0.09%; p = 0.04). Initial troponin I levels were comparable (+ COCN: 0.3 ± 3.2 ng/mL vs. -COCN: 0.7 ± 4.7 ng/mL, p < 0.001).Cocaine positivity in ED chest pain patients was not associated with a clinically meaningful increase in 30-day MACE. These findings support incorporating + COCN patients into standard, risk-based chest pain pathways rather than reflexive admission or over-testing.
Indexed as
Identifiers
41203967What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.